Compendium of Cancer Genome Aberrations

HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion: Difference between revisions

(View all pending changes)
[pending revision][pending revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{DISPLAYTITLE:Acute myeloid leukaemia with BCR::ABL1 fusion}}
{{DISPLAYTITLE:Acute myeloid leukaemia with BCR::ABL1 fusion}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]


Line 38: Line 39:
|+
|+
|WHO Essential Criteria (Genetics)*
|WHO Essential Criteria (Genetics)*
|a myeloid neoplasm with >20% blasts expressing a myeloid immunophenotype in the bone marrow and/or peripheral blood; detection of ''BCR::ABL1'' at initial diagnosis; lack of features of chronic myeloid leukaemia (CML) before or at diagnosis or after therapy.
|Detection of ''BCR::ABL1'' at initial diagnosis.
|-
|-
|WHO Desirable Criteria (Genetics)*
|WHO Desirable Criteria (Genetics)*
|presence of t(9;22)(q34;q11.2) on conventional karyotyping; determination of the ''BCR::ABL1'' transcript subtype and establishment of a baseline level of ''BCR::ABL1'' transcript subtype and establishment of a baseline level of ''BCR::ABL1'' transcript for monitoring treatment response.
|Presence of t(9;22)(q34;q11.2) on conventional karyotyping; determination of the ''BCR::ABL1'' transcript subtype and establishment of a baseline level of ''BCR::ABL1'' transcript subtype and establishment of a baseline level of ''BCR::ABL1'' transcript for monitoring treatment response.
|-
|-
|Other Classification
|Other Classification
Retrieved from "https://test.ccga.io/index.php/HAEM5:Acute_myeloid_leukaemia_with_BCR::ABL1_fusion"